In June 2022 schülke joined the Science Based Targets Initiative (SBTi) which shows the company’s clear focus on further advancing its climate protection activities based on the latest results of science-based climate studies. schülke has thus committed itself to meeting the goals of the Paris Climate Agreement. In March 2023, schülke submitted its specific targets to SBTi – which have now been validated.
SBTi is a collaboration between the Carbon Disclosure Project (CDP), the UN Global Compact, the World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). The initiative takes proven science-based procedures and evaluates corresponding targets of companies on an independent basis. Around 6,500 companies worldwide are currently collaborating with SBTi.
Reducing the carbon footprint is a core element of the sustainability strategy
Before schülke submitted its climate targets to SBTi a comprehensive analysis of the company’s global ecological footprint of 2021 was carried out: emissions in Scopes 1, 2 and 3 were recorded, evaluated and a structured procedure to track progress was established. To clarify: Scope 1 indicates the direct emissions caused, e.g. by the combustion of fossil fuels in production or by other processes within the company itself. Scope 2 indicates indirect emissions that are generated through purchases like those of energy or electricity. Finally, Scope 3 indicates indirect emissions within the value chain that are generated by activities that take place before or after procedures crucial for business.
Based on its CO2 emissions of 2021 considering all 3 scopes mentioned, schülke has developed concrete targets to reduce its emissions by 2030, which have now been validated by SBTi. schülke CEO Jan-Dirk Auris says about this milestone: "The fact that the targets from schülke have now been recognized by SBTi is an outstanding achievement made possible by the entire schülke workforce worldwide, who have been collecting data and developed our targets. By now all of us are convinced that ecological sustainability is a central pillar of our future viability as a company."
The company’s path towards greater sustainability
As part of its commitment to its climate targets, schülke is continuously reducing its use of energy and resources with the help of modern technologies. Furthermore, the company challenges its product portfolio to make it even more sustainable. The consistent high-quality standard and effectiveness of the products to ensure the safety of patients and healthcare professionals remain a given.
The mission of schülke to take responsibility for current and future generations extends beyond company borders. "With reliable and more sustainably produced products, we reassure our customers in their purchasing decisions and also support them in their own efforts to act sustainably," says Jan-Dirk Auris.
Further information on the commitment of schülke and its sustainability targets can be found here: https://www.schuelke.com/intl-en/about-us/responsibility/sustainability.php
Schülke & Mayr GmbH (schülke)
Schülke & Mayr GmbH, with its headquarters in Norderstedt near Hamburg, has been a global leader in infection prevention and control for almost 135 years. Infectious germs know no borders - this has always been the case and is even more common in today's globalized world. Committed to the mission "We protect lives worldwide", the strategic business areas of schülke Healthcare, Over the Counter (OTC), Life Sciences and Direct Patient Care actively contribute to the safety and health protection of people. With strong brands such as octenisept®, kodan®, desderman® or microshield®, schülke is one of the international market leaders in the field of wound and mucous membrane antisepsis as well as hand and surface disinfection in German hospitals. People in more than 80 countries around the world rely on schülke products every day. With its wide range of high-quality and innovative products, expert advice and reliable service, schülke offers holistic concepts for infection treatment and control in professional healthcare, for end users and the pharmaceutical sector. Schülke consists of more than 1,100 dedicated employees, over 20 subsidiaries and three production sites in Germany (schülke), France (Bioxal) and Brazil (Vic Pharma). In 2022, schülke contributed to protecting patients and health care professionals in hospitals from infections with nearly three billion product applications.
You can find more information about schülke here: www.schuelke.com